Collegium Pharmaceutical, Inc. COLL Symproic — 2029
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree.
The official record: Collegium Pharmaceutical, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Collegium Pharmaceutical, Inc.'s symproic — 2029.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Collegium Pharmaceutical, Inc.'s symproic — 2029?
- Collegium Pharmaceutical, Inc. (COLL) reported symproic — 2029 of $7.29M in Q1 2026.
- How has Collegium Pharmaceutical, Inc.'s symproic — 2029 changed year-over-year?
- Collegium Pharmaceutical, Inc.'s symproic — 2029 decreased by 0.0% year-over-year, from $7.29M to $7.29M.
- What is the long-term trend for Collegium Pharmaceutical, Inc.'s symproic — 2029?
- Over 2 years (2022 to 2024), Collegium Pharmaceutical, Inc.'s symproic — 2029 has grown at a 0.0% compound annual growth rate (CAGR), from $29.14M to $29.14M.
- What does symproic — 2029 mean?
- The projected amortization expense for Symproic-related intangible assets specifically for the fiscal year 2029. This metric is used to estimate the long-term impact of intangible asset depreciation on future financial results.